




MOLECULAR TARGETING TECHNOLOGIES, INC.

Translating Targeted Radiotherapeutics into Tomorrow's Medicine

^{177}Lu -DOTA-EB-TATE

The first and only long-acting PRRT for SSTR2+ cancers




Recently reported* a 3-year follow-up to a landmark study (3 cycles at 8-12 week intervals, 3.7 GBq/cycle) against GEP-NET, after a median follow-up of 46 months:

- Favorable disease control (86.2% in 29 patients)
- Encouraging median, 36-month Progression Free Survival
- Higher Objective Response Rate than SOC (33% vs. 13% by RECIST)
- Good safety & tolerability
- Lower dose & fewer cycles than SOC reduces total radiation by 60%

**Theranostics* 2022; 12(15):6437-6445


EBTATE™ Improved PK/PD vs. SOC

EBTATE reached peak slower and had a prolonged plateau



EBTATE (blue) vs. Lutathera (red)

EBTATE showed 7.9-fold increase in tumor uptake vs. ^{177}Lu -DOTA-TATE (SOC)



Challenges

- GEP - NET incidence 5.8/100K
- Current treatments have efficacy limitations
- Multiple, high doses of ^{177}Lu -DOTA-TATE (SOC) may cause kidney toxicity

Solution

~80% of NETs overexpress somatostatin receptors. EBTATE was designed to extend *in vivo* half-life over SOC.

Technology

Incorporates Evans Blue in the somatostatin analog backbone, significantly increasing residence in albumin, a virtual slow-release system. Multiple global patents.

Proof of Concept

Multiple preclinical and clinical trials in the US and China show improved safety and efficacy.

Funding

Closed Series A funding for asset development.

Next

Phase I & I/III trials through 2023-2026 in 3 indications

MTTI

Molecular Targeting Technologies, Inc. is clinical stage biotech developing novel, targeted peptide receptor radiotherapeutics (PRRT) for disease treatment.

Contact: cpak@mtarget.com

More information: www.evathera.com

Currently collaborating on trials in Hürthle Cell Thyroid and Nasopharyngeal cancers.